The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Hypogammaglobulinemia, infection risk, and IgG replacement therapy in myeloma
Wolfgang Willenbacher, MD, Medical University of Innsbruck, Innsbruck, Austria, discusses real-world data from the Austrian Myeloma Registry on hypogammaglobulinemia, infection risk, and immunoglobulin replacement therapy in patients with multiple myeloma. He highlights the increased infection risk associated with IgG levels below 500 mg/dL and the potential for replacement therapy to reduce infection-related hospitalizations, emphasizing proactive monitoring and prevention. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
